Study guide
11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
Key Takeaways Explain This Topic AI
Cutaneous leukocytoclastic vasculitis (CLCV) manifests as dependent, non-blanching palpable purpura; histopathology demonstrates postcapillary venule fibrinoid necrosis, neutrophil infiltration with leukocytoclasia (nuclear dust), and erythrocyte extravasation, with direct immunofluorescence (DIF) yielding peak diagnostic accuracy within the initial 24 to 48 hours of lesion onset.
IgA vasculitis (Henoch-Schönlein purpura) is defined by vascular IgA immune complex deposition on DIF and a classic tetrad of palpable purpura, arthralgias, gastrointestinal colic, and glomerulonephritis, mandating serial urinalysis and blood pressure monitoring for at least six months.
ANCA-associated vasculitides present distinctive cutaneous features alongside systemic disease: granulomatosis with polyangiitis (GPA, c-ANCA/anti-PR3) produces upper/lower respiratory granulomas and purpura; eosinophilic granulomatosis with polyangiitis (EGPA, p-ANCA/anti-MPO) combines severe late-onset asthma, peripheral eosinophilia, and necrotizing vasculitis.
Cutaneous polyarteritis nodosa (cPAN) affects medium-sized muscular arteries at the dermal-subcutaneous junction, presenting with livedo racemosa, tender subcutaneous nodules, and digital ulcerations without visceral involvement, requiring deep incisional or wedge biopsy down to the subcutis for histological confirmation.
Neutrophilic dermatoses must be carefully differentiated from vasculitis and infections: Pyoderma gangrenosum presents with painful ulcers featuring undermined violaceous borders and pathergy, where sharp surgical debridement is strictly contraindicated; Sweet syndrome exhibits abrupt febrile succulent plaques, dermal neutrophilia without vasculitis, and dramatic responsiveness to systemic corticosteroids.
Last updated: September 2026
- 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
- Cutaneous Vasculitis: Classification & Vessel Size Paradigm
Cutaneous vasculitis comprises a heterogeneous group of inflammatory diseases characterized by destruction of blood vessel walls. In dermatological practice, diagnostic classification is anchored to the 2012 Revised Chapel Hill Consensus Conference (CHCC) Nomenclature , adapted to vessel caliber in cutaneous tissue:
Small-Vessel Vasculitis (SVV): Affects postcapillary venules, arterioles, and capillaries in the superficial/mid-dermis. Hallmark morphology: Palpable purpura .
Medium-Vessel Vasculitis (MVV): Affects muscular arteries at the dermal-subcutaneous fat junction and panniculus. Hallmark morphology: Subcutaneous nodules, livedo racemosa, punched-out necrotic ulcers, digital gangrene .
Large-Vessel Vasculitis (LVV): Giant cell arteritis and Takayasu arteritis; primarily extracutaneous, but can manifest scalp necrosis or limb claudication. ┌────────────────────────────────────────────────────────┐
- │ Cutaneous Vasculitis Spectrum │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌───────────────────────────────────────────────┴───────────────────────────────────────────────┐
- │ │
- ┌───────────────▼───────────────┐ ┌───────────────▼───────────────┐
- │ Small-Vessel Vasculitis │ │ Medium-Vessel Vasculitis │
- │ (Postcapillary Venules) │ │ (Muscular Arteries / Fat Jct)│
- └───────────────┬───────────────┘ └───────────────┬───────────────┘
- │ │
- ├─ Cutaneous Leukocytoclastic Vasculitis (CLCV) ├─ Systemic Polyarteritis Nodosa (PAN)
- ├─ IgA Vasculitis (Henoch-Schönlein purpura) │ (HBV-associated, microaneurysms, spares lungs)
- ├─ Urticarial Vasculitis (NUV vs HUV) └─ Cutaneous PAN (cPAN)
- ├─ Cryoglobulinaemic Vasculitis (Type I / II / III) (Livedo racemosa, tender nodules, benign course)
└─ ANCA-Associated Vasculitides (AAV):
- ├─ Granulomatosis with Polyangiitis (GPA; c-ANCA / PR3)
- ├─ Microscopic Polyangiitis (MPA; p-ANCA / MPO)
- └─ Eosinophilic GPA (EGPA; p-ANCA / MPO, asthma, eosinophils)
- Small-Vessel Vasculitides
- 1. Cutaneous Leukocytoclastic Vasculitis (CLCV)
CLCV (hypersensitivity vasculitis) is the most common cutaneous vasculitis. It is confined to the skin in up to 70% of cases or represents the cutaneous manifestation of systemic immune-complex disease.
Clinical Presentation: Palpable purpura —non-blanching, 1 to 3 mm discrete or coalescing violaceous papules. Lesions demonstrate a strict gravity-dependent distribution , concentrating on the lower legs, ankles, and feet (or over sacral pressure points in bedridden patients). Lesions may develop central hemorrhagic vesicles, bullae, or superficial ulcerations.
Etiological Triggers:
Infections (~30%): Group A beta-hemolytic streptococcal upper respiratory infections, hepatitis B/C, HIV, infective endocarditis.
Medications (~15–20%): Beta-lactams, sulfonamides, NSAIDs, thiazides, allopurinol, propylthiouracil, hydralazine.
Systemic Autoimmune Diseases (~15%): SLE, rheumatoid arthritis, Sjögren syndrome.
Malignancies (~5%): Paraneoplastic, predominantly lymphoproliferative disorders (multiple myeloma, hairy cell leukemia, lymphoma) and solid tumors.
Idiopathic (~40–50%): Exhaustive clinical workup reveals no identifiable trigger.
Histopathology & The Critical Direct Immunofluorescence (DIF) Window
H&E Histological Triad of CLCV:
Fibrinoid Necrosis: Deposition of homogeneous, eosinophilic, smudgy fibrin within the walls of postcapillary venules.
Neutrophilic Infiltrate with Leukocytoclasia: Dense transmural and perivascular neutrophils undergoing apoptotic degeneration and nuclear fragmentation ( karyorrhexis ), producing scattered basophilic fragments known as "nuclear dust" .
Erythrocyte Extravasation & Endothelial Swelling: Red blood cells leaking through breached venular walls into the surrounding dermis (generating the non-blanching purpuric color), accompanied by plump, damaged endothelial cells.
THE 24-TO-48-HOUR DIF WINDOW RULE (KEY FACT):
Punch biopsy for direct immunofluorescence (DIF) must be taken from a fresh, early lesion (<24 to 48 hours old) .
In lesions older than 48 hours, migrating neutrophils and tissue macrophages phagocytose and degrade the vascular immune complexes and complement fragments, yielding a false-negative DIF result.
DIF reveals granular perivascular deposits of C3, IgM, IgG, or IgA within venular walls.
2. IgA Vasculitis (IgAV / Henoch-Schönlein Purpura)
IgA vasculitis is an immune-complex small-vessel vasculitis mediated by the deposition of abnormal galactose-deficient IgA1 (Gd-IgA1) immune complexes.
Epidemiology: The most common systemic vasculitis in pediatric patients (peak incidence 4–7 years), but occurs in adults, where it carries a significantly higher risk of chronic, progressive renal disease.
The Classical Diagnostic Tetrad:
Palpable Purpura: Symmetrically distributed across the extensor lower extremities, buttocks, and perineum; generally spares the trunk and face in children.
Arthralgia / Arthritis: Non-erosive, periarticular swelling affecting knees and ankles (up to 75%).
Gastrointestinal Symptoms (50–75%): Colicky abdominal pain, nausea, vomiting, bowel ischaemia, and gastrointestinal haemorrhage (melaena/haematochezia). Intussusception is uncommon (a few per cent of children) and, unlike idiopathic childhood intussusception, is usually ileo-ileal .
Renal Involvement (IgA Nephropathy): Mesangial proliferative glomerulonephritis; manifests as microscopic hematuria, red cell casts, proteinuria, hypertension, or nephrotic syndrome (40–50%).
Direct Immunofluorescence Hallmark: Bright, granular, vascular IgA deposition (frequently with C3) in the walls of superficial dermal postcapillary venules.
Mandatory Surveillance Protocol: Renal involvement dictates long-term prognosis. European guidelines mandate regular screening with blood pressure and urinalysis (proteinuria/hematuria) at diagnosis, weekly for the first month, biweekly through month 3, and monthly for at least 6 months .
3. Urticarial Vasculitis
Characterized by urticarial wheals that demonstrate vasculitic features upon clinical and histological scrutiny.
Clinical Discriminators (Urticaria vs Urticarial Vasculitis):
Individual lesion duration: Ordinary urticaria resolves within <24 hours in a given site; urticarial vasculitis plaques persist >24 to 72 hours in the exact same location.
Sensory symptoms: Ordinary urticaria is intensely pruritic; urticarial vasculitis wheals cause burning, stinging, or tenderness .
Resolution morphology: Resolves with residual purpura or post-inflammatory hyperpigmentation (hemosiderin staining) due to red blood cell extravasation.
Histopathology: Demonstrates true leukocytoclastic vasculitis.
Classification & Systemic Association:
Normocomplementaemic Urticarial Vasculitis (NUV): Normal serum C3/C4/C1q; usually idiopathic, benign, cutaneous-limited, with low systemic risk.
Hypocomplementaemic Urticarial Vasculitis (HUV): Markedly depressed C3, C4, and C1q, with circulating anti-C1q autoantibodies .
HUV is strongly associated with underlying SLE or represents Hypocomplementaemic Urticarial Vasculitis Syndrome (HUVS / McDuffie Syndrome) : characterized by severe obstructive pulmonary disease (severe emphysema, chronic cough), recurrent angioedema, ocular inflammation (episcleritis, uveitis), and glomerulonephritis.
4. Cryoglobulinaemic Vasculitis
Cryoglobulins are immunoglobulins that reversibly precipitate in vitro at temperatures <37°C and redissolve upon rewarming.
Brouet Classification:
Type I (Monoclonal): Monoclonal IgG or IgM (without rheumatoid factor activity). Associated with hematologic malignancies: multiple myeloma, Waldenström macroglobulinemia, monoclonal gammopathy of undetermined significance (MGUS) . Pathogenesis: Non-inflammatory vascular occlusion and hyperviscosity. Morphology: Acrocyanosis, digital gangrene, cold-induced retiform purpura, livedo, punched-out leg ulcers.
Type II (Mixed Cryoglobulinemia): Monoclonal IgM (with rheumatoid factor activity) directed against polyclonal IgG. Strongly associated with Hepatitis C Virus (HCV) infection (>80–90%) .
Type III (Mixed Cryoglobulinemia): Polyclonal IgM (with RF activity) directed against polyclonal IgG. Associated with HCV, chronic infections, SLE, and Sjögren syndrome.
Clinical Presentation in Mixed Cryoglobulinemia (Type II & III):
Meltzer's Triad: Palpable purpura (lower legs), arthralgias , and asthenia (severe fatigue) .
Peripheral sensorimotor polyneuropathy (mononeuritis multiplex) and membranoproliferative glomerulonephritis (MPGN).
Diagnostic Serology: Profoundly depressed serum C4 is universal (often undetectable, while C3 is mildly reduced or normal); positive rheumatoid factor (RF); detectable cryocrit (blood collection and transport must strictly occur in pre-warmed tubes maintained at 37°C prior to clotting to avoid false-negative results!). First-line therapy for HCV-associated mixed cryoglobulinemia: direct-acting antiviral (DAA) therapy ± rituximab.
ANCA-Associated Vasculitides (AAV)
AAV encompasses systemic necrotizing small-vessel vasculitides linked to antineutrophil cytoplasmic antibodies (ANCA):
- Feature Granulomatosis with Polyangiitis (GPA) Microscopic Polyangiitis (MPA) Eosinophilic GPA (EGPA)
- Eponym Formerly Wegener's Granulomatosis — Formerly Churg-Strauss Syndrome
Primary Serology c-ANCA / Anti-Proteinase 3 (anti-PR3) (>90%) p-ANCA / Anti-Myeloperoxidase (anti-MPO) (~75–80%) p-ANCA / Anti-MPO (40–50%)
Respiratory Manifestations Upper (sinusitis, epistaxis, saddle-nose deformity ) & lower cavitary nodules Pulmonary capillaritis, diffuse alveolar hemorrhage Severe late-onset asthma, allergic rhinitis , transient pulmonary infiltrates
Renal Manifestations Necrotizing crescentic glomerulonephritis Rapidly progressive glomerulonephritis Mild glomerulonephritis (predominantly in ANCA-positive subset)
Cutaneous Features Palpable purpura, necrotic ulcers ( PG-like ), strawberry gingivitis Palpable purpura, livedo reticularis, splinter hemorrhages Tender subcutaneous nodules, palpable purpura, urticaria
Histopathology Necrotizing granulomas + leukocytoclastic vasculitis Pauci-immune necrotizing vasculitis ( no granulomas ) Extravascular eosinophilic granulomas + eosinophil-rich vasculitis
Medium-Vessel Vasculitis: Polyarteritis Nodosa (PAN)
Polyarteritis nodosa is a systemic or cutaneous necrotizing arteritis targeting medium-sized and small muscular arteries. Crucial Rule: PAN spares postcapillary venules and arterioles, does not cause glomerulonephritis, and does not involve pulmonary circulation.
1. Systemic Polyarteritis Nodosa (sPAN)
Etiology: Strongly associated with Hepatitis B Virus (HBV) surface antigenemia (immune complex deposition), as well as idiopathic and genetic forms (deficiency of adenosine deaminase 2 [DADA2]).
Clinical Manifestations: Systemic hypertension (renal artery vasculitis inducing ischemia), renal microaneurysms (demonstrated on mesenteric/renal digital subtraction angiography), peripheral neuropathy (asymmetric wrist/foot drop: mononeuritis multiplex ), gastrointestinal ischemia/infarction, orchitis/testicular pain.
2. Cutaneous Polyarteritis Nodosa (cPAN)
Clinical Scope: A chronic, relapsing, benign form confined entirely to the skin and peripheral neuromuscular system of the limbs , without visceral involvement.
Cutaneous Morphology:
Tender Subcutaneous Nodules: Painful, 0.5 to 2 cm subcutaneous nodules distributed along the course of muscular arteries on the lower legs.
Livedo Racemosa: Irregular, broken, asymmetric, jagged violaceous reticular rings that do not reverse with warmth (unlike physiologic livedo reticularis).
"Starburst" Livedo: Clusters of branching livedoid macules surrounding malleolar ulcerations.
Punched-Out Ulcerations & Digital Gangrene: Secondary to ischemic occlusion.
THE BIOPSY TECHNIQUE PEARL (KEY PITFALL):
Standard punch biopsies are inadequate and yield false-negative results because they only sample the superficial dermis.
Definitive diagnosis requires a deep incisional or wedge biopsy down into the subcutaneous fat , specifically targeting the active, indurated margin of a tender nodule to capture muscular arteries at the dermal-subcutaneous junction.
Histology shows transmural segmental necrotizing arteritis of muscular arteries with fibrinoid necrosis, internal elastic lamina disruption (Verhoeff-van Gieson stain), and mixed neutrophil/mononuclear infiltration.
Neutrophilic Dermatoses Spectrum
Neutrophilic dermatoses are non-infectious, autoinflammatory conditions characterized by dense, sheet-like dermal neutrophilic infiltration in the complete absence of primary leukocytoclastic vasculitis or microbial pathogens. ┌────────────────────────────────────────────────────────┐
- │ Neutrophilic Dermatoses Spectrum │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌───────────────────────────────┴───────────────────────────────┐
- │ │
- ┌───────────────▼───────────────┐ ┌───────────────▼───────────────┐
- │ Pyoderma Gangrenosum │ │ Sweet Syndrome │
- │ (PG) │ │ (Acute Febrile Neutrophilic) │
- └───────────────┬───────────────┘ └───────────────┬───────────────┘
- │ │
- ├─ Sterile follicular pustule / nodule ├─ Sudden tender erythematous succulent plaques
- ├─ Painful ulcer with undermined violaceous border ├─ "Pseudovesicular" mamillated surface
- ├─ Cribriform "cigarette-paper" scarring ├─ High spiking fevers (>38°C)
- ├─ Pathergy phenomenon (NO surgical debridement!) ├─ Peripheral neutrophilic leukocytosis
- ├─ Associations: IBD, MDS, IgA Gammopathy, RA ├─ Associations: AML/MDS, G-CSF, IBD, Infections
- └─ First-line: Corticosteroids / Ciclosporin / Infliximab └─ First-line: Systemic Corticosteroids (rapid)
- 1. Pyoderma Gangrenosum (PG)
Pyoderma gangrenosum is a sterile, ulcerative autoinflammatory neutrophilic dermatosis driven by hyperactive innate immunity, dysregulated neutrophil trafficking, and excessive pro-inflammatory cytokines (IL-1beta, IL-8, IL-17, TNF-alpha).
Clinical Morphology & Stages
Primary Lesion: Begins acutely as an erythematous follicular papule, pustule, or fluctuant furunculoid nodule.
Ulcerative Breakdown: Rapidly breaks down within days to form an excruciatingly painful ulcer.
Hallmark Ulcer Edge: Violaceous, gunmetal-colored, ragged, edematous, overhanging, and deeply undermined border surrounded by a vibrant halo of erythema.
Ulcer Base: Purulent, beefy-red granulation tissue covered with yellowish necrotic sludge, mucinous exudate, or hemorrhagic crust.
Healing Architecture: Heals with characteristic cribriform (sieve-like, perforated) or "cigarette-paper" atrophic scars .
Atypical Clinical Variants:
Bullous PG: Vesiculobullous lesions with central necrosis, predilection for upper extremities and face; strongly linked to hematologic malignancies (MDS, AML) .
Pustular PG: Multiple sterile pustules surrounded by erythema; associated with active Inflammatory Bowel Disease flares.
Vegetative / Superficial Granulomatous PG: Indolent, superficial, non-undermined verrucous plaques; less aggressive, responds well to conservative or topical therapy.
Peristomal PG: Develops adjacent to abdominal stomas in patients with ulcerative colitis or Crohn's disease.
The Pathergy Phenomenon & Surgical Contraindication
Pathergy: Induction of new inflammatory lesions or dramatic, catastrophic enlargement of existing ulcers following minor, trivial cutaneous trauma (venipuncture, needle sticks, surgical incisions, debridement).
THE CARDINAL CLINICAL RULE / HIGH-STAKES EXAM POINT:
Sharp surgical debridement is strictly contraindicated in active pyoderma gangrenosum!
Aggressive surgical debridement or wedge excision performed under the mistaken diagnosis of a bacterial abscess, necrotizing fasciitis, or venous stasis ulcer induces rapid, explosive ulcer extension ( pathergic exacerbation ).
Incision and drainage of suspected abscesses must be deferred until PG is ruled out.
Systemic Disease Associations of PG
Up to 70% of pyoderma gangrenosum cases occur in association with an underlying systemic disorder :
Inflammatory Bowel Disease (~30%): Ulcerative Colitis (more frequent) > Crohn's disease . Note: PG activity does not always parallel the clinical activity of the underlying intestinal disease; ulcers can erupt during complete clinical remission of colitis.
Hematologic Malignancies & Gammopathies (~20%): Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Monoclonal Gammopathy (classically IgA Monoclonal Gammopathy) .
Arthropathies (~15–20%): Rheumatoid arthritis, seronegative spondyloarthropathies.
Monogenic Autoinflammatory Syndromes: PAPA Syndrome (Pyogenic sterile Arthritis, Pyoderma gangrenosum, and severe cystic Acne; autosomal dominant mutation in PSTPIP1 ).
Validated Diagnostic Criteria (Delphi Consensus Criteria for Ulcerative PG)
Diagnosis requires meeting the Major Criterion plus at least 4 of 8 Minor Criteria :
Major Criterion: Biopsy of ulcer edge showing a dense dermal neutrophilic infiltrate without evidence of infectious pathogens or true leukocytoclastic vasculitis.
Minor Criteria:
Exclusion of infection (negative bacterial, fungal, and mycobacterial cultures).
Pathergy phenomenon (ulcer worsening after minor trauma or history of pathergy).
History of Inflammatory Bowel Disease or inflammatory arthritis.
History of papule, pustule, or vesicle ulcerating within 4 days of onset.
Peripheral erythema, undermined border, and exquisite tenderness.
Multiple ulcerations, at least one on an anterior lower leg.
Cribriform or "cigarette paper" scarring at healed sites.
Decrease in ulcer size within 1 month of initiating systemic immunosuppression.
European Management Guidelines for PG
First-Line Systemic Therapy:
Systemic Corticosteroids: Oral prednisone (0.5 to 1.0 mg/kg/day) or intravenous pulsed methylprednisolone (1 g/day for 3 days) for rapid induction of remission.
Oral Ciclosporin: 3 to 5 mg/kg/day; in the randomised STOP-GAP trial, ciclosporin and prednisolone gave similar healing rates and similar overall adverse-event rates.
Second-Line Biologic Therapy:
Infliximab: Chimeric anti-TNF-alpha monoclonal antibody (5 mg/kg at weeks 0, 2, 6, then every 8 weeks); the only biologic agent validated in a randomized, placebo-controlled trial for PG.
Adalimumab, Ustekinumab (anti-IL-12/23), Anakinra (IL-1 receptor antagonist).
Wound Care: Gentle, non-adherent, absorbent dressings; negative pressure wound therapy (only after systemic disease is well controlled); avoid aggressive mechanical washing.
2. Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
Sweet syndrome is characterized by the sudden onset of fever, peripheral neutrophilia, and tender cutaneous plaques driven by cytokine-mediated (G-CSF, IL-1, IL-6) neutrophil activation.
Clinical Triad & Morphology
Succulent Cutaneous Plaques: Abrupt onset of discrete, tender, edematous, erythematous-to-violaceous succulent papules, plaques, and nodules. The surface frequently exhibits a characteristic mamillated or "pseudovesicular" appearance (extreme, massive edema of the papillary dermis causing light reflection resembling fluid-filled vesicles, though needle aspiration yields no fluid).
Systemic Symptoms: High, spiking fevers (>38°C) , malaise, headache, arthralgias, and myalgias.
Laboratory Markers: Marked peripheral blood neutrophilia (absolute neutrophil count >8,000/microL; >70% neutrophils), elevated C-reactive protein (CRP), and high ESR.
Diagnostic Criteria (Su & Liu / Modified von den Driesch Criteria)
Diagnosis requires meeting both Major Criteria and at least 2 of 4 Minor Criteria :
Major Criteria:
Abrupt onset of painful erythematous plaques or nodules.
Histopathologic evidence of a dense, sheet-like dermal neutrophilic infiltrate without leukocytoclastic vasculitis.
Minor Criteria:
Pyrexia (fever > 38°C).
Associated underlying condition: hematologic or visceral malignancy, inflammatory bowel disease, pregnancy, or preceding upper respiratory/gastrointestinal infection.
Excellent and rapid response to systemic corticosteroid therapy.
Abnormal laboratory values at presentation (3 of 4: ESR > 20 mm/hr, positive CRP, leukocytosis >8,000/microL, neutrophils >70%).
Malignancy-Associated Sweet Syndrome (MASS)
Approximately 15% to 20% of Sweet syndrome cases are paraneoplastic (MASS) :
Hematologic Neoplasms Predominate: Acute Myeloid Leukemia (AML) accounts for the vast majority, alongside myelodysplastic syndrome (MDS) and chronic myeloid leukemia.
Atypical Diagnostic Clues for MASS:
Eruption of bullous, pustular, or ulcerative lesions that mimic pyoderma gangrenosum.
Prominent oral mucosal involvement (bullae, ulcers).
Absence of peripheral leukocytosis: Paradoxically, patients with MASS may present with cytopenias (anemia, neutropenia, or thrombocytopenia) due to underlying leukemic marrow infiltration!
Histopathology showing "histiocytoid" immature myeloid cells (Histiocytoid Sweet Syndrome).
Drug-Induced Sweet Syndrome
Granulocyte Colony-Stimulating Factor (G-CSF / filgrastim, pegfilgrastim): The most common causative agent, occurring during neutrophil count recovery following chemotherapy.
Other recognized drugs: All-trans retinoic acid (ATRA), bortezomib, trimethoprim-sulfamethoxazole, furosemide.
Management Protocol for Sweet Syndrome
First-Line Therapy: Systemic Corticosteroids (Prednisone 0.5 to 1.0 mg/kg/day) produce dramatic, miraculous clinical defervescence within 24 to 48 hours, followed by rapid clearing of cutaneous plaques over 1 to 2 weeks. Tapered over 4 to 6 weeks to prevent relapse.
Steroid-Sparing First-Line Alternatives:
Potassium Iodide (SSKI): 300 mg three times daily (inhibits neutrophil chemotaxis).
Colchicine: 0.5 mg twice or three times daily.
Dapsone: 100 to 150 mg daily (check G6PD prior to therapy).
Indomethacin: 50 mg three times daily.